Ionis Pharmaceuticals Analyst Price Targets - Benzinga

Ionis Pharmaceuticals Inc

IONSNASDAQ

Trade with Public

Trade with Public

$58.09

-0.04-0.07%

In chiusura: Sep 4, 5:00 PM EST

$52.29

-5.80-9.98%

Post-mercato: Sep 4, 7:58 PM EST

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Ionis Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ionis Pharmaceuticals (IONS).

Price Target Range — 7 Quarters

Analyst Consensus — 22 Analysts

1S.Buy

16Buy

5Hold

Consensus RatingBuy# Analysts22Avg. Consensus PT$87Upside to Avg. PT+67.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 4, 2026	Needham	Joseph Stringer	Maintained	Buy	$86
Sep 4, 2026	BMO Capital	David Lebowitz	PT Raise	Market Perform	$60→$61
Sep 4, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$115
Aug 31, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$115
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform→Market Perform	$60
Aug 3, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$72→$76
Jul 30, 2026	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$100→$95
Jul 30, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$125→$115
Jul 21, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$106→$89
Jul 16, 2026	Wolfe Research	Andy Chen	Downgrade	Outperform→Peer Perform	—
Jul 13, 2026	RBC Capital	Luca Issi	PT Cut	Outperform	$100→$85
Jul 10, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$130→$125
Jul 10, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$130→$110
Jul 10, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$115→$90
Jul 10, 2026	Canaccord Genuity	Gary Nachman	PT Cut	Buy	$110→$95
Jul 10, 2026	Citigroup	Eric Joseph	PT Cut	Buy	$115→$100
Jul 9, 2026	Jefferies	Akash Tewari	PT Cut	Buy	$113→$90
Jul 9, 2026	Needham	Joseph Stringer	PT Cut	Buy	$105→$86
Jun 25, 2026	Goldman Sachs	Salveen Richter	PT Raise	Neutral	$74→$75
Jun 25, 2026	Leerink Partners	Mani Foroohar	PT Raise	Outperform	$122→$129

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $86 Price Target

Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $86 price target.

Benzinga Newsdesk

PRO
BMO Capital Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $61

BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $60 to $61.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $115 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $115 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $115 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $115 price target.

Benzinga Newsdesk

This Allstate Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

Wall Street analysts changed outlook on top names. Check all rating changes, including upgrades/downgrades, on Benzinga analyst ratings page.

Avi Kapoor

This Merck Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Wall Street analysts upgraded PGR, MRK, EPR and initiated coverage on BEKE and IONS. Check analyst ratings and price targets for these stocks.

Avi Kapoor